Literature DB >> 23041123

Adverse events following a third dose of measles, mumps, and rubella vaccine in a mumps outbreak.

Glen R Abedi1, Jeffry D Mutuc, Jacqueline Lawler, Zanie C Leroy, Jean M Hudson, Debra S Blog, Cynthia R Schulte, Elizabeth Rausch-Phung, Ikechukwu U Ogbuanu, Kathleen Gallagher, Preeta K Kutty.   

Abstract

During a 2009-2010 mumps outbreak in a New York State village, a third dose of measles, mumps, and rubella (MMR) vaccine was administered to children in three schools as a control measure. Information on local and systemic adverse events (AE) was collected by a self-report survey distributed to all children in grades 6-12. A comprehensive search for AE following MMR vaccination was conducted using physician records and the Vaccine Adverse Events Reporting System (VAERS). A literature search was performed for published reports pertaining to AE associated with mumps-containing vaccine, using the Jeryl-Lynn strain, from 1969 to 2011. A total of 1755 individuals received the third dose; 1597 (91.0%) returned the survey. Of those, 115 (7.2%) reported at least one local or systemic AE in the 2 weeks following vaccination. The most commonly reported AE were "pain, redness, or swelling at the injection site" (3.6%) and "joint or muscle aches" (1.8%). No serious AE were reported in the survey, physician records or through VAERS. The proportions of AE found in the present study were lower than or within the range of those reported in prior studies of first- and second-dose MMR vaccine studies. The results of this study suggest that a third dose of MMR vaccine administered in an outbreak setting is safe, with injection site reactions reported more frequently than systemic reactions. However, to assess risk for rare or serious AE after a third dose of MMR vaccine, longer term studies would be required.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23041123     DOI: 10.1016/j.vaccine.2012.09.053

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Epidemiology and the economic assessment of a mumps outbreak in a highly vaccinated population, Orange County, New York, 2009-2010.

Authors:  Preeta Krishnan Kutty; Jacqueline Lawler; Elizabeth Rausch-Phung; Ismael R Ortega-Sanchez; Stephen Goodell; Cynthia Schulte; Lynn Pollock; Barbara Valure; Jean Hudson; Kathleen Gallagher; Debra Blog
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

2.  Using a scripted data entry process to transfer legacy immunization data while transitioning between electronic medical record systems.

Authors:  J Michel; A Hsiao; A Fenick
Journal:  Appl Clin Inform       Date:  2014-03-26       Impact factor: 2.342

Review 3.  Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity.

Authors:  Eugene Lam; Jennifer B Rosen; Jane R Zucker
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

4.  Increasing vaccination rates requires a better understanding of vaccine hesitancy.

Authors:  Joshua P Bennett
Journal:  CMAJ       Date:  2019-10-21       Impact factor: 8.262

5.  Differential durability of immune responses to measles and mumps following MMR vaccination.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Antonia Thomas; Beth R Larrabee; Steven Rubin; Gregory A Poland
Journal:  Vaccine       Date:  2019-02-20       Impact factor: 3.641

6.  Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak.

Authors:  Mona Marin; Mariel Marlow; Kelly L Moore; Manisha Patel
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-01-12       Impact factor: 17.586

7.  Research protocol of two concurrent cluster-randomized trials: Real-life Effect of a CAMPaign with Measles Vaccination (RECAMP-MV) and Real-life Effect of a CAMPaign with Oral Polio Vaccination (RECAMP-OPV) on mortality and morbidity among children in rural Guinea-Bissau.

Authors:  A Varma; A K G Jensen; S M Thysen; L M Pedersen; P Aaby; A B Fisker
Journal:  BMC Public Health       Date:  2019-11-11       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.